GLP-1 10MG
GLP-1 10MG Vial is a high-purity research-grade peptide designed to support advanced investigation of glucagon-like peptide‑1 biology. As a GLP‑1 receptor agonist analog, this product enables precise exploration of incretin signaling, metabolic regulation, and endocrine function in preclinical models. Supplied in a convenient vial format, GLP‑1 10MG is ideal for laboratories studying glucose homeostasis, appetite modulation, and body weight regulation under tightly controlled experimental conditions. For laboratory research use only. Not for human or veterinary use.
$148.75
🚚 Free shipping on all orders (US Only )
🔄 All sales are final
FDA Disclaimer:Â The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. All products are for laboratory developmental research USE ONLY. Products are not for human consumption.
Overview
– Supports investigation of **GLP‑1 receptor–mediated incretin signaling** in metabolic research models
– Enables controlled studies of **glucose homeostasis, insulin secretion, and glycemic regulation**
– Facilitates preclinical exploration of **appetite, satiety, and body‑weight modulation**
– Provided as a **high-purity peptide in vial format** for flexible protocol design and reconstitution
– Suitable for **in vitro and in vivo preclinical research** under professional laboratory conditions
Structure
GLP‑1 10MG represents a long-acting GLP‑1 receptor agonist–type peptide with close sequence homology to native human GLP‑1(7‑36) amide. GLP‑1 family peptides are linear polypeptides of 30–31 amino acids, typically derived from the proglucagon sequence and characterized by an N‑terminal histidine–alanine motif that is critical for GLP‑1 receptor activation. Structural optimization in GLP‑1 analogs commonly focuses on enhancing resistance to dipeptidyl peptidase‑4 (DPP‑4) cleavage at the N‑terminus and improving albumin or plasma protein binding to extend circulating half‑life, while maintaining the helical conformation required for high-affinity receptor engagement.
Research
GLP‑1 10MG Vial is intended for research on the glucagon-like peptide‑1 pathway, a central regulator of postprandial metabolism. GLP‑1 receptor agonist analogs are widely used to study incretin-mediated enhancement of glucose-dependent insulin secretion, suppression of glucagon release, and modulation of gastric emptying. In preclinical systems, activation of GLP‑1 receptors in pancreatic islets, the gastrointestinal tract, and the central nervous system allows detailed characterization of signaling cascades governing energy balance, appetite, and glycemic control. This product provides a controlled tool for dissecting these mechanisms in metabolic and endocrine research models.
Referenced Citations
Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. *Cell Metabolism, 27*(4), 740–756. https://doi.org/10.1016/j.cmet.2018.03.001
Nauck, M. A., & Meier, J. J. (2019). Incretin hormones: Their role in health and disease. *Diabetes, Obesity and Metabolism, 21*(S1), 5–21. https://doi.org/10.1111/dom.13603
Capehorn, M. S., Catarig, A. M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., & Vergès, B. (2020). Efficacy and safety of GLP‑1 receptor agonists in type 2 diabetes: An evidence-based review. *Diabetes Therapy, 11*(8), 1905–1943. https://doi.org/10.1007/s13300-020-00846-1
Holst, J. J. (2022). The physiology of glucagon-like peptide 1. *Physiological Reviews, 102*(4), 1565–1622. https://doi.org/10.1152/physrev.00034.2020